uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Walid Abi-Saab sold 1,466 shares of the company's stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $13.92, for a total transaction of $20,406.72. Following the completion of the sale, the insider directly owned 150,437 shares of the company's stock, valued at $2,094,083.04. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
uniQure Stock Performance
Shares of QURE stock traded up $0.21 during trading on Friday, reaching $14.49. 328,148 shares of the company's stock traded hands, compared to its average volume of 1,960,399. The firm's 50-day moving average is $14.53 and its 200 day moving average is $13.98. The company has a market capitalization of $793.49 million, a P/E ratio of -3.30 and a beta of 0.08. uniQure N.V. has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a current ratio of 11.99, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53.
uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. Equities research analysts expect that uniQure N.V. will post -3.75 EPS for the current year.
Analysts Set New Price Targets
Several research firms have recently issued reports on QURE. Guggenheim reaffirmed a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of uniQure in a research report on Thursday, May 29th. Chardan Capital reiterated a "buy" rating and set a $38.00 target price on shares of uniQure in a research note on Friday, May 30th. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Finally, Wall Street Zen lowered shares of uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.82.
Read Our Latest Stock Report on QURE
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its holdings in shares of uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after buying an additional 502,684 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in uniQure during the 4th quarter worth approximately $320,000. Assenagon Asset Management S.A. lifted its stake in uniQure by 355.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock worth $3,550,000 after purchasing an additional 261,323 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in uniQure in the 4th quarter worth approximately $1,951,000. Finally, Northern Trust Corp boosted its holdings in uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after purchasing an additional 1,923 shares during the period. Institutional investors own 78.83% of the company's stock.
About uniQure
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Featured Stories

Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.